CClinicalTrials.gg
CompletedNCT01583257Updated May 15, 2015

Pilot Study: Active Video Gaming to Facilitate Physical Activity and Quality of Life in Kidney Transplant Recipients

A Phase 1/2 interventional study of Workout based on active video gaming in Quality of Life, sponsored by Nova Scotia Health Authority. Completed at 1 site in Canada. Per ClinicalTrials.gov, last updated 2015-05-15.

Sponsored by Nova Scotia Health Authority · Phase 1/2 and Interventional

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Sex
All
01

Study summary

Background:

Renal transplant recipients have a greater risk of morbidity and mortality primarily due to cardiovascular disease when compared to the general population. Cardiovascular disease is responsible for 50% to 60% percent of deaths amongst renal transplant population and death from cardiovascular disease is a leading cause of functioning graft loss.

Physical activity is an effective form of secondary prevention in existing cardiovascular disease reducing all-cause mortality by 25%-30% and has demonstrated positive effects overall on quality of life and well-being. Transplant patients who participated in regular cardiovascular exercise have significant more positive scores on the SF-36 Health Status Questionnaire in comparison to inactive transplant recipients.

Active video gaming is evolving as an innovative method to increase physical activity. Active video gaming has supported physical activity in children and youth. There is however a paucity of literature examining interactive games as a means to facilitate physical activity and its impact on CVD and quality of life in the adult population nor any literature examining AVG and its impact on an adult surgical population.

This pilot study is designed to determine if Active Video Gaming is feasible and is able to lead to behavioral modifications and Quality of Life improvement.

Subject Selection:

This is a pilot study during which 10 patients who have undergone renal transplant will be selected to exercise with Active Video Gaming for a duration of 3 months. The program activity will begin 6 months post surgery.

02

Conditions studied

  • Quality of Life
03

In context

Lead sponsor

Nova Scotia Health Authority is the lead sponsor of 255 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Renal transplant patient who want and are able to take part in this study

Exclusion criteria

Exclusion Criteria:

  • Cardiac or pulmonary dysfunction diagnosed through preoperative assessment.
  • Any surgical complication incurred with transplantation.
  • Peripheral vascular disease.
05

Study design

Phase
Phase 1 / Phase 2
Allocation
Not applicable
Intervention model
Single group
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Active Video Gaming

    An active gaming exercise workout will be provided with QoL measured at baseline and following the 8 week workout schedule. The workout will use the Microsoft Kinect (TM) system with EA Sports Active 2 program.

    Behavioral: Workout based on active video gaming

Interventions

  • BehavioralWorkout based on active video gaming

    A personalized workout regimen will be provided using the Microsoft Kinect Active Gaming Console with EA Sports Active 2 program

    Also known as: Microsoft Kinect, EA Sports Active 2

06

What researchers measure

Primary outcomes

  1. Quality of Life

    Quality of life will be measured at baseline and upon completion of the intervention using a standard questionnaire.

    Time frame: 3 months post intervention

07

Study locations

1 site
  • QEII Health Sciences Center, MOTP
    Halifax, Nova Scotia B3H 2Y9, Canada
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 15, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01583257
Lead sponsor
Nova Scotia Health Authority
Collaborators
Novartis Pharmaceuticals
Responsible party
Sponsor
First posted
Apr 23, 2012
Start date
Jun 2012
Primary completion
Jun 2013
Completion
Jun 2013
Last update
May 15, 2015

Study contacts

Ian P Alwayn, MD, PhD
principal investigator · CDHA / Dalhousie University

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion